MLYS at a glance
Mineralys Therapeutics, Inc. (MLYS, SEC CIK 1933414) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Mineralys Therapeutics, Inc. (MLYS) shares worth $838.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Congleton Jon on September 30, 2026 of 75,000 shares at $25.46 per share.
- In the last 90 days, MLYS insiders reported 0 open-market purchases ($0) and 12 open-market sales ($6.6M) on Form 4, a net sale of $6.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$6.6M
- 13F holders
- 28 funds
- $838.6M · −1 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Business section lacks substantive description of core operations or products
- Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
- No disclosure of new products, services, strategic shifts, or geographic expansions this year
- References Ernst & Young LLP as principal independent auditor for 2026 financial statements
- Unusual focus on compliance codes and proxy statement incorporation, minimal direct business narrative
Risk Factors
- Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
- Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
- Supply chain risk: Dependency on third-party CMOs for cGMP-compliant manufacturing scale-up of lorundrostat, potential delays and cost increases
- Competitive risk: Market acceptance risk due to potential competing products and alternative therapies affecting lorundrostat launch prospects
- Financial risk: Accumulated deficit $457.2M with net losses $154.7M in 2025; need substantial capital raises risking dilution or restrictive debt covenants
Management Discussion & Analysis
- No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
- R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
- No segments disclosed; entire focus on lorundrostat development and clinical trials
- Cash, cash equivalents, and investments $656.6M at year-end 2025; raised $269.6M in Sept 2025, $188.7M in Mar 2025, and $139.6M via ATM offering through Mar 2026
- Management expects cash to fund operations for at least 12 months; key risk is timing and success of regulatory approval and clinical trial outcomes
AI summary of the MLYS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales before lorundrostat approval
- Net loss $241.1M vs $43.3M YoY; R&D expense $221.4M vs $38.3M
- R&D expenses increased $183.1M, primarily reflecting the $200.0M Tanabe upfront payment
- Cash, equivalents, and investments $661.4M at June 30, 2026; $100.0M Tranche A Loan drawn
- PDUFA target date December 22, 2026; anticipated headwinds include FDA feedback, tariffs, inflation, and geopolitical conflict
Risk Factors
- New debt-servicing risk triggered by June 2026 Loan Agreement, with maturity in 2031 and no expected operating cash flow
- Secured-credit risk from lender security interests covering substantially all assets, including intellectual property
- Covenant-compliance risk from minimum liquidity and future net product revenue requirements beginning 2028
- Default risk includes potential acceleration, collateral foreclosure, and required repayment of principal, interest, and premiums
- Competitive disadvantage from increased leverage versus better-capitalized competitors
AI summary of the MLYS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Full results and management commentary contained in Exhibit 99.1 press release
Item 5.02: Departure/Appointment of Directors or Principal Officers
- James J. Ferguson III, M.D. appointed Chief Medical Officer effective August 10, 2026
- David Rodman, M.D. replaced as CMO but remains full-time Strategic Advisor
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $241.1M, driven by the $200.0M Tanabe upfront payment and higher commercial preparation costs
- Cash, equivalents and investments $661.4M, expected to fund operations through 2028 including lorundrostat launch
Item 8.01: Other Events
- $142.5 million expected net proceeds from sale of 5,660,378 common shares
- Offering price $26.50 per share, with underwriters purchasing at $25.3075
Item 1.01: Entry into a Material Definitive Agreement
- Company expects to finalize Tanabe agreement terminating the license and assigning lorundrostat intellectual-property rights to Mineralys
- Full ownership could reduce licensing dependence and strengthen commercialization economics if FDA approves lorundrostat
AI summaries of MLYS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MLYS
Don't miss the next MLYS filing
- Alerts as it files. A push when MLYS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MLYS, by share count.
- Ask anything. An AI agent that reads every MLYS filing and answers with sources.
MLYS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Congleton Jon | Sell | Sep 30, 2026 | 75,000 | $25.46 |
| Slingsby Brian Taylor | Sell | Sep 22, 2026 | 104,320 | $28.81 |
| Warren Eric | M | Sep 21, 2026 | 7,438 | $13.24 |
| Warren Eric | Sell | Sep 21, 2026 | 7,438 | $28.12 |
| Warren Eric | M | Sep 21, 2026 | 7,438 | - |
| Karydas Daphne | M | Sep 15, 2026 | 3,000 | $12.02 |
| Karydas Daphne | M | Sep 15, 2026 | 3,000 | - |
| Karydas Daphne | Sell | Sep 15, 2026 | 3,000 | $28.58 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$84.7M | -$192.4M | -$170.6M | |
| Net Income | -$71.9M | -$177.8M | -$154.7M | |
| Balance Sheet | ||||
| Total Assets | $251.6M | $205.9M | $661.8M | |
| Equity | $241.2M | $191.3M | $646.7M | |
| ROE | -29.8% | -93.0% | -23.9% | |
| Per Share | ||||
| EPS | $-1.99 | $-3.66 | $-2.29 | |
| Cash Flow | ||||
| Operating CF | -$81.2M | -$166.3M | -$142.4M | |
Source: XBRL data in Mineralys Therapeutics, Inc. (MLYS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MLYS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $838.6M |
| Q1 2026 | 29 | $685.5M |
| Q4 2025 | 26 | $876.5M |
| Q3 2025 | 25 | $740.8M |
| Q2 2025 | 27 | $171.1M |
| Q1 2025 | 22 | $127.5M |
| Q4 2024 | 13 | $70.0M |
| Q3 2024 | 10 | $37.0M |
- BlackRock+1.41M (+31%)
- State Street Corp+1.21M (+41%)
- Invesco Ltd+1.05M (+2479%)
- T. Rowe Price Group+919.2K (+68%)
- Millennium Management+696.5K (+133%)
- D.E. Shaw & Co−534.5K (-60%)
- FMR LLC (Fidelity)−349.4K (-7%)
- Ameriprise Financial−192.7K (-87%)
- Two Sigma Investments−149.4K (-48%)
- Franklin Resources−149.1K (-8%)
- Raymond James Financial−24.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MLYS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 20, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jul 15, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MLYS SEC filings: frequently asked questions
Are MLYS insiders buying or selling?
In the last 90 days, Mineralys Therapeutics, Inc. (MLYS) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $6.6 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MLYS stock?
As of June 30, 2026, the largest Mineralys Therapeutics, Inc. (MLYS) holders among the 13F filers tracked by SignalX were BlackRock ($158.8 million), FMR LLC (Fidelity) ($121.7 million), State Street Corp ($111.7 million), Vanguard Capital Management LLC ($74.4 million), T. Rowe Price Group ($61.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in MLYS's latest 10-K?
In the 10-K filed March 12, 2026, Mineralys Therapeutics, Inc. (MLYS) flagged: Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue. Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations. (AI summary of the Risk Factors section.)
What did MLYS report in its latest 8-K?
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.
What are the latest MLYS SEC filings?
Mineralys Therapeutics, Inc. (MLYS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on October 2, 2026.
What is MLYS's SEC CIK number?
Mineralys Therapeutics, Inc. (MLYS)'s SEC Central Index Key (CIK) is 1933414. EDGAR lists every MLYS filing under that number.
Ask anything about MLYS
The research agent reads MLYS's filings, financials, insider trades and 13F holders, then answers with sources.